Page 106 - Read Online

Falconer et al. MT-MMPs in prostate cancer

activity, bone matrix turnover, and tumor cell proliferation in prostate Med Res Rev 2008;28:155-83.
cancer bone metastasis. J Natl Cancer Inst 2002;94:17-25. 72. Atkinson JM, Falconer RA, Edwards DR, Pennington CJ, Siller
61. Bonfil RD, Dong Z, Trindade Filho JC, Sabbota A, Osenkowski P, CS, Shnyder SD, Bibby MC, Patterson LH, Loadman PM, Gill JH.
Nabha S, Yamamoto H, Chinni SR, Zhao H, Mobashery S, Vessella Development of a novel tumor-targeted vascular disrupting agent
RL, Fridman R, Cher ML. Prostate cancer-associated membrane activated by membrane-type matrix metalloproteinases. Cancer Res
type 1-matrix metalloproteinase: a pivotal role in bone response and 2010;70:6902-12.
intraosseous tumor growth. Am J Pathol 2007;170:2100-11. 73. Gill JH, Loadman PM, Shnyder SD, Cooper P, Atkinson JM, Ribeiro
62. Sabbota AL, Kim HR, Zhe X, Fridman R, Bonfil RD, Cher ML. Morais G, Patterson LH, Falconer RA. Tumor-targeted prodrug
Shedding of RANKL by tumor-associated MT1-MMP activates Src- ICT2588 demonstrates therapeutic activity against solid tumors
dependent prostate cancer cell migration. Cancer Res 2010;70:5558- and reduced potential for cardiovascular toxicity. Mol Pharm
66. 2014;11:1294-300.
63. Huang CF, Lira C, Chu K, Bilen MA, Lee YC, Ye X, Kim SM, Ortiz 74. Loadman PM, Gimenez-Warren J, Mitchell A, Race AD, Spencer JA,
A, Wu FL, Logothetis CJ, Yu-Lee LY, Lin SH. Cadherin-11 increases Shnyder SD, Gill JH, Falconer RA. Improved delivery of paclitaxel
migration and invasion of prostate cancer cells and enhances their to prostate tumors: a membrane-type matrix metalloproteinase (MT-
interaction with osteoblasts. Cancer Res 2010;70:4580-9. MMP)-targeted approach. Cancer Res 2016;76:2054.
64. Kawaguchi J, Azuma Y, Hoshi K, Kii I, Takeshita S, Ohta T, Ozawa H, 75. Graff JN, Beer TM. Should docetaxel be administered earlier in
Takeichi M, Chisaka O, Kudo A. Targeted disruption of cadherin-11 prostate cancer therapy? Expert Rev Anticancer Ther 2015;15:977-9.
leads to a reduction in bone density in calvaria and long bone 76. James ND, Spears MR, Clarke NW, Dearnaley DP, De Bono JS,
metaphyses. J Bone Miner Res 2001;16:1265-71. Gale J, Hetherington J, Hoskin PJ, Jones RJ, Laing R, Lester JF,
65. Cathcart J, Pulkoski-Gross A, Cao J. Targeting matrix McLaren D, Parker CC, Parmar MK, Ritchie AW, Russell JM, Strebel
metalloproteinases in cancer: bringing new life to old ideas. Genes RT, Thalmann GN, Mason MD, Sydes MR. Survival with newly
Dis 2015;2:26-34. diagnosed metastatic prostate cancer in the “docetaxel rra”: data from
66. Vartak DG, Gemeinhart RA. Matrix metalloproteases: underutilized 917 Patients in the control arm of the STAMPEDE Trial (MRC PR08,
targets for drug delivery. J Drug Target 2007;15:1-20. CRUK/06/019). Eur Urol 2015;67:1028-38.
67. Deryugina EI, Quigley JP. Tumor angiogenesis: MMP-mediated 77. James ND, Sydes MR, Clarke NW, Mason MD, Dearnaley DP,
induction of intravasation- and metastasis-sustaining neovasculature. Spears MR, Ritchie AW, Parker CC, Russell JM, Attard G, de Bono J,
Matrix Biol 2015;44-46:94-112. Cross W, Jones RJ, Thalmann G, Amos C, Matheson D, Millman R,
68. Lafleur MA, Handsley MM, Knauper V, Murphy G, Edwards DR. Alzouebi M, Beesley S, Birtle AJ, Brock S, Cathomas R, Chakraborti
Endothelial tubulogenesis within fibrin gels specifically requires the P, Chowdhury S, Cook A, Elliott T, Gale J, Gibbs S, Graham JD,
activity of membrane-type-matrix metalloproteinases (MT-MMPs). J Hetherington J, Hughes R, Laing R, McKinna F, McLaren DB,
Cell Sci 2002;115:3427-38. O’Sullivan JM, Parikh O, Peedell C, Protheroe A, Robinson AJ, Srihari
69. Zawilska JB, Wojcieszak J, Olejniczak AB. Prodrugs: a challenge for N, Srinivasan R, Staffurth J, Sundar S, Tolan S, Tsang D, Wagstaff J,
the drug development. Pharmacol Rep 2013;65:1-14. Parmar MK. Addition of docetaxel, zoledronic acid, or both to first-
70. Barve A, Jin W, Cheng K. Prostate cancer relevant antigens and line long-term hormone therapy in prostate cancer (STAMPEDE):
enzymes for targeted drug delivery. J Control Release 2014;187:118- survival results from an adaptive, multiarm, multistage, platform
32. randomised controlled trial. Lancet 2016;387:1163-77.
71. Bhattacharyya B, Panda D, Gupta S, Banerjee M. Anti-mitotic activity 78. Bonfil RD, Cher ML. The role of proteolytic enzymes in metastatic
of colchicine and the structural basis for its interaction with tubulin. bone disease. IBMS BoneKEy 2011;8:16-36.

Journal of Cancer Metastasis and Treatment ¦ Volume 3 ¦ December 12, 2017 327